Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2019
The 9th European Lung Cancer Conference
Geneva, Switzerland - 10 Apr - 13 Apr 2019
Presentation Date(s):- 10 Apr - 13 Apr 2019
- Total Presentations: 489
-
+
ESMO Colloquium supported by Lilly Oncology in collaboration with MSD - How to best use immune checkpoint inhibitors in NSCLC: Single agents or combined with chemotherapy?
- Type: ESMO Colloquium
- Presentations: 7
- Coordinates: 4/10/2019, 04:45 - 06:15, Room A
-
+
What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors?
12:10 - 12:30 | Presenter: Marina Chiara Garassino
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Proffered Paper session I
- Type: Proffered Paper session
- Presentations: 8
- Coordinates: 4/10/2019, 16:30 - 18:15, Room C
-
+
LBA2 - Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)
17:30 - 17:45 | Presenter: Marina Chiara Garassino
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
17:45 - 18:00 | Presenter: Niels Reinmuth
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Lunch & Poster Display session
- Type: Poster Display session
- Presentations: 170
- Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
-
+
23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)
12:30 - 12:30 | Presenter: Roberto Ferrara
- Abstract
Loading... -
+
82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy
12:30 - 12:30 | Presenter: Solange Peters
- Abstract
Loading... -
+
101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
12:30 - 12:30 | Presenter: Nicolas Girard
- Abstract
Loading... -
+
150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
12:30 - 12:30 | Presenter: Giulia Galli
- Abstract
Loading... -
+
160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
12:30 - 12:30 | Presenter: Arsela Prelaj
- Abstract
Loading... -
+
188TiP - Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial
12:30 - 12:30 | Presenter: Giulia Galli
- Abstract
Loading...
-
+
Management of side effects and toxicities
- Type: Educational session
- Presentations: 6
- Coordinates: 4/11/2019, 14:45 - 16:15, Room A
-
+
Management of pulmonary toxicities: Clinical case
15:00 - 15:15 | Presenter: Marina Chiara Garassino
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Mini Oral session II
- Type: Mini Oral session
- Presentations: 9
- Coordinates: 4/11/2019, 16:40 - 17:40, Room C
-
+
85O - Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)
16:45 - 16:50 | Presenter: David Planchard
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Medscape Oncology - Industry Satellite Symposium
- Type: Industry Satellite symposium
- Presentations: 6
- Coordinates: 4/11/2019, 18:00 - 19:00, Room C
-
+
The expanding treatment armamentarium in ALK-positive NSCLC: The evidence
18:20 - 18:35 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
Case challenge 1: First-line options - Considerations for treatment choice
18:35 - 18:45 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
AstraZeneca - Industry Satellite Symposium
- Type: Industry Satellite symposium
- Presentations: 10
- Coordinates: 4/12/2019, 16:30 - 17:30, Room A
-
+
Considerations for first-line treatment selection for patients with metastatic EGFRm NSCLC
16:35 - 16:45 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
Panel discussion
17:00 - 17:00 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
Panel discussion
17:10 - 17:10 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
Panel discussion
17:25 - 17:25 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
